Table 1. BzR Affinity for Compounds 14–16a.
Ki (nM) or % inhibition (10 μM)b,c |
||||||
---|---|---|---|---|---|---|
cpd | R1 | X | bovine brain membranes | α1β2γ2 | α2β2γ2 | α5β3γ2 |
14c | H | H | 120 ± 11 | 346 ± 29 | 39% ± 3 | 46% ± 5 |
15d | NO2 | H | 117 ± 12 | 65 ± 5 | 32% ± 3 | 44% ± 4 |
16e | NO2 | CH3 | 88 ± 6 | 31.3 ± 2 | 0% | 0% |
diazepam | 10 ± 1 | |||||
flumazenil | 0.90 ± 0.05 | |||||
clonazepam | 0.85 ± 0.02 |
Ki (nM) or % inhibition (10 μM) data of indol-3-ylglyoxylylamide derivatives 14–16.
Ki represents the means ± SEM of three determinations performed in triplicate.
Inhibition percentages of specific [3H]-flumazenil binding at 10 μM represent the means ± SEM of three determinations performed in triplicate.
Data are from Da Settimo et al.50
Data are from Primofiore et al.52